HYFT
MindWalk Holdings Corp.
Biotechnology · Healthcare · United States
1.13
close · 2026-10-30
value
17
cheaper than peers17
quality
44
stronger fundamentals44
ranked against
Biotechnology (commercial)
value
quality
162 peerswide variation
Value inputs
| measure | company | vs peers |
| price to sales | 3.46× | 77 |
| cash flow yield, 2 years ago | -8.5% | 50 |
| cash flow yield, 1 year ago | -13.4% | 43 |
| earnings yield, latest year | -27.4% | 36 |
| cash flow yield, latest year | -23.9% | 30 |
| cash flow yield, 3 years ago | -39.7% | 21 |
| price to book | 10.80× | 19 |
| earnings yield, 2 years ago | -90.3% | 17 |
| earnings yield, 3 years ago | -94.7% | 16 |
| earnings yield, 1 year ago | -79.6% | 16 |
10 of 12 measures available
Quality inputs
| measure | company | vs peers |
| revenue growth | 49.8% | 67 |
| operating margin | -105.2% | 55 |
| debt to equity | 30.0% | 38 |
| return on equity | -85.4% | 30 |
4 of 4 measures available
Facts
| market cap | $54M |
| free cash flow | -$5.5M |
| employees | 74 |
| first trade | 2002-01-07 |
| next earnings | 2026-09-14 |
| fundamentals updated | 2026-09-14 |
Annual history
| measure | 2026 | 2025 | 2024 | 2023 |
| diluted eps | -0.31 | -0.90 | -1.02 | -1.07 |
| free cash flow | -$12.9M | -$7.2M | -$4.6M | -$21.3M |
| net income | -$13.9M | -$30.2M | -$26.1M | -$26.6M |
| revenue | $15.6M | $10.6M | $10.3M | $20.7M |
| unusual items | -$735,000 | -$21.7M | -$15.0M | -$2.2M |